Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label exploratory dose-finding study of Sym001 in adults with immune thrombocytopenic purpura
2007-006081-15Phase 2Completed
- Sponsor
- Symphogen
- Start
- Feb 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rozrolimupab in immune thrombocytopenia (ITP), sponsored by Symphogen. Primary endpoint: Incidence and severity of adverse events. Started Feb 2008; status: completed.
02
Drugs
Rozrolimupab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2007-006081-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006081-15.